🇨🇭·10h agoIndustry
U.S. FDA grants Priority Review for Roche’s Enspryng for MOGAD, an autoimmune disease with no approved treatments
Publisher
R
Roche Newsroom
Switzerland
This page provides publisher metadata, and related coverage to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Roche Newsroom
- Region
- Switzerland
- Scope
- Industry
- Published
- September 10, 2026
Publisher context, original article off-platform
This page presents the title, publisher metadata, and related coverage. The publisher did not provide a public summary in this feed. Full-text reading stays on the publisher's original site.
Source route
Continue on roche.com
Leave the platform to read the original full article on the publisher site.
Source: Roche Newsroom
Scope: Industry
Related coverage
More related coverage
Chugai Pharmaceutical News/6h ago
エンスプリングに関するロシュ社の発表について（MOG抗体関連疾患に対するFDAによる申請受理および優先審査指定）
Chugai Pharmaceutical/6h ago
Roche Announces U.S. FDA Grants Priority Review for Enspryng for Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)
Ipsen/6h ago
Why evidence matters: Seema Meloni on making data meaningful
Ipsen RSS/6h ago